|
|
||||||||




*
Department of Internal Medicine, Section on Pulmonary and Critical Care Medicine, Divisions of
Infectious Diseases, and
Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157; and
Human Studies Division, National Health and Environmental Effects Research Laboratory, Chapel Hill, NC 27599
This study tested the hypothesis that certain secretory
phospholipase A2 (sPLA2) isotypes act in a
cytokine-like fashion through cell surface receptors to influence mast
cell survival. Initial experiments revealed that sPLA2
activity and sPLA2 receptor expression are increased, and
mast cells lost their capacity to maintain membrane asymmetry upon
cytokine depletion. Groups IB and III, but not group IIA
PLA2, prevented the loss of membrane asymmetry. Similarly,
group IB prevented nucleosomal DNA fragmentation in mast cells.
Providing putative products of sPLA2 hydrolysis to
cytokine-depleted mast cells did not influence survival. Furthermore,
catalytic inactivation of sPLA2 did not alter its capacity
to prevent apoptosis. Inhibition of protein synthesis using
cycloheximide or actinomycin reversed the antiapoptotic effect of
sPLA2. Additionally, both wild-type and catalytically
inactive group IB PLA2 induced IL-3 synthesis in mast
cells. However, adding IL-3-neutralizing Ab did not change
Annexin VFITC binding and only partially inhibited
thymidine incorporation in sPLA2-supplemented mast cells.
In contrast, IL-3-neutralizing Ab inhibited both Annexin
VFITC binding and thymidine incorporation in mast cells
maintained with IL-3. sPLA2 enhanced phosphoinositide
3'-kinase activity, and a specific inhibitor of phosphoinositide
3'-kinase reversed the antiapoptotic effects of sPLA2.
Likewise, sPLA2 increased the degradation of I-
B
, and
specific inhibitors of nuclear factor
activation (NF-
B) reversed
the antiapoptotic effects of sPLA2. Together, these
experiments reveal that certain isotypes of sPLA2 enhance
the survival of mast cells in a cytokine-like fashion by activating
antiapoptotic signaling pathways independent of IL-3 and probably via
sPLA2 receptors rather than sPLA2 catalytic
products.
This article has been cited by other articles:
![]() |
D Shoseyov, H Bibi, S Offer, O Schwob, M Krimsky, M Kleiman, and S Yedgar Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A2 Thorax, September 1, 2005; 60(9): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Granata, A. Petraroli, E. Boilard, S. Bezzine, J. Bollinger, L. Del Vecchio, M. H. Gelb, G. Lambeau, G. Marone, and M. Triggiani Activation of Cytokine Production by Secreted Phospholipase A2 in Human Lung Macrophages Expressing the M-Type Receptor J. Immunol., January 1, 2005; 174(1): 464 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Triggiani, F. Granata, B. Balestrieri, A. Petraroli, G. Scalia, L. Del Vecchio, and G. Marone Secretory Phospholipases A2 Activate Selective Functions in Human Eosinophils J. Immunol., March 15, 2003; 170(6): 3279 - 3288. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |